MetaVia's Studies Accepted at ADA Conference Boosts Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Should l Buy MTVA?
MetaVia Inc's stock surged by 79.28% in pre-market trading as it crossed above the 5-day SMA, reflecting strong investor interest.
The catalyst for this movement stems from the acceptance of three key studies on DA-1726 and vanoglipel for presentation at the American Diabetes Association's 2026 Scientific Sessions. DA-1726, a novel dual agonist currently in a 16-week Phase 1 trial, aims to provide a differentiated treatment option for obesity, while vanoglipel shows potential in treating liver and metabolic diseases, enhancing MetaVia's reputation in the biotech sector.
This positive news not only highlights MetaVia's research capabilities but also positions the company favorably for future market opportunities, particularly with upcoming clinical trial data expected in Q4 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MTVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MTVA
Wall Street analysts forecast MTVA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.110
Low
40.00
Averages
47.50
High
55.00
Current: 1.110
Low
40.00
Averages
47.50
High
55.00
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MetaVia's Three Key Studies Accepted at ADA Conference
- Research Highlights: MetaVia's three abstracts on DA-1726 and vanoglipel have been accepted for presentation at the American Diabetes Association's 2026 Scientific Sessions, showcasing the company's strength in cardiometabolic disease research and potentially enhancing its reputation in the biotech sector.
- DA-1726's Potential: As a novel dual agonist, DA-1726 is currently undergoing a 16-week Phase 1 trial aimed at achieving higher therapeutic doses with improved tolerability, which, if successful, could provide a differentiated treatment option for obesity and significantly boost market share.
- Vanoglipel's Broad Applications: Vanoglipel has demonstrated extensive therapeutic potential in multiple preclinical studies for liver and metabolic diseases, particularly in combination therapies for metabolic dysfunction-associated steatohepatitis and Type 2 diabetes, potentially opening new market opportunities for the company.
- Future Data Release: MetaVia plans to report clinical trial data for DA-1726 in Q4 2026, which will provide critical business development insights for investors and may influence the company's future financing and market strategies.
See More
MetaVia Reports Q1 2026 Financial Results
- Earnings Performance: MetaVia reported a GAAP EPS of -$0.79 for Q1 2026, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Stable Other Income: Total other income for the first quarter was approximately $200,000, consistent with the same period in 2025, suggesting no significant changes in revenue from non-core operations, which may limit overall financial growth potential.
- Operating Expenses Increase: Total operating expenses for Q1 2026 were approximately $4.0 million, slightly up from $3.9 million in Q1 2025, primarily due to higher G&A expenses, indicating pressure on cost control measures within the company.
- R&D Expense Decline: Despite the rise in overall operating expenses, R&D expenses decreased, partially offsetting the increase in G&A costs, which may reflect a cautious approach to innovation investment, potentially impacting future product development and market competitiveness.
See More
MetaVia's DA-1726 to be Presented at EASL Congress
- Clinical Research Advancement: MetaVia announced that a late-breaking abstract for its drug DA-1726 will be presented at the 2026 EASL Congress, highlighting the drug's potential in obesity treatment, which is expected to attract investor interest and enhance the company's profile.
- Best-in-Class Potential: DA-1726, as a dual agonist, has shown superior weight loss and glucose control effects in clinical trials, with the 32 mg dose demonstrating excellent results in the multiple ascending dose trial, potentially providing a competitive edge in the market.
- Mechanism Advantage: Compared to existing GLP-1 receptor agonists, DA-1726 exhibited better weight loss outcomes in mouse models while allowing for increased food intake, showcasing its unique pharmacological mechanism and clinical application prospects.
- Future Outlook: MetaVia plans to release clinical data for DA-1726 in Q4 2026, and if results are positive, it will further strengthen its positioning in the obesity treatment market and enhance the company's leadership in the biotechnology sector.
See More
MetaVia's DA-1726 to be Presented at EASL Congress
- Clinical Research Advancement: MetaVia's DA-1726, a novel dual agonist, has been accepted for poster presentation at the 2026 EASL Congress, highlighting its potential in obesity treatment and likely attracting investor and industry attention.
- Dose Optimization Study: Currently undergoing a 16-week Phase 1 Part 3 titration study, DA-1726 aims to optimize tolerability at higher doses, with data expected in Q4 2026, which will provide critical insights into its market potential.
- Superior Clinical Performance: In preclinical mouse models, DA-1726 demonstrated better weight loss compared to the existing GLP-1 agonist semaglutide, while still allowing increased food intake, showcasing its unique pharmacological advantages.
- Strategic Development Focus: With a commitment to transforming cardiometabolic diseases, the successful development of DA-1726 will further solidify MetaVia's leadership in the biotechnology sector and potentially drive future commercialization efforts.
See More
MetaVia Initiates Phase 1 Trial for DA-1726 in Obesity
- Trial Commencement: MetaVia has successfully dosed the first patient in its Phase 1 clinical trial for DA-1726, marking a significant step towards evaluating higher doses safely, which could bring new hope for obesity treatment.
- Dose Optimization Strategy: The trial is divided into two cohorts utilizing one-step and two-step dose escalation strategies aimed at safely achieving therapeutic doses of 48mg and 64mg, potentially enhancing patient tolerability and efficacy significantly.
- Promising Initial Results: At the 48mg dose, patients experienced an average weight loss of approximately 9%, alongside meaningful reductions in waist circumference and improved glycemic control, highlighting DA-1726's potential in treating obesity and related metabolic disorders.
- Future Data Expectations: More data is anticipated in the fourth quarter of 2026, with MetaVia aiming to further demonstrate DA-1726's unique efficacy and competitive advantage in the market.
See More
MetaVia Initiates Phase 1 Trial for DA-1726
- Clinical Trial Progress: MetaVia announced that the first patient has been dosed in its Phase 1 clinical trial for DA-1726, marking a significant step towards evaluating higher doses safely, which could provide new solutions for obesity treatment.
- Dose Optimization Strategy: The trial consists of two 16-week cohorts designed to assess one-step and two-step dose escalation strategies aimed at safely achieving higher therapeutic doses, thereby enhancing patient tolerability and efficacy.
- Significant Preliminary Results: At the 48 mg dose, patients experienced an average weight loss of approximately 9%, alongside meaningful reductions in waist circumference and improved glycemic control, indicating DA-1726's potential superiority over existing therapies.
- Future Outlook: More data is expected in the fourth quarter of 2026, as MetaVia focuses on further demonstrating DA-1726's efficacy, aiming for breakthrough advancements in obesity and related metabolic diseases.
See More
MetaVia's Three Key Studies Accepted at ADA Conference
- Research Highlights: MetaVia's three abstracts on DA-1726 and vanoglipel have been accepted for presentation at the American Diabetes Association's 2026 Scientific Sessions, showcasing the company's strength in cardiometabolic disease research and potentially enhancing its reputation in the biotech sector.
- DA-1726's Potential: As a novel dual agonist, DA-1726 is currently undergoing a 16-week Phase 1 trial aimed at achieving higher therapeutic doses with improved tolerability, which, if successful, could provide a differentiated treatment option for obesity and significantly boost market share.
- Vanoglipel's Broad Applications: Vanoglipel has demonstrated extensive therapeutic potential in multiple preclinical studies for liver and metabolic diseases, particularly in combination therapies for metabolic dysfunction-associated steatohepatitis and Type 2 diabetes, potentially opening new market opportunities for the company.
- Future Data Release: MetaVia plans to report clinical trial data for DA-1726 in Q4 2026, which will provide critical business development insights for investors and may influence the company's future financing and market strategies.
See More
MetaVia Reports Q1 2026 Financial Results
- Earnings Performance: MetaVia reported a GAAP EPS of -$0.79 for Q1 2026, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Stable Other Income: Total other income for the first quarter was approximately $200,000, consistent with the same period in 2025, suggesting no significant changes in revenue from non-core operations, which may limit overall financial growth potential.
- Operating Expenses Increase: Total operating expenses for Q1 2026 were approximately $4.0 million, slightly up from $3.9 million in Q1 2025, primarily due to higher G&A expenses, indicating pressure on cost control measures within the company.
- R&D Expense Decline: Despite the rise in overall operating expenses, R&D expenses decreased, partially offsetting the increase in G&A costs, which may reflect a cautious approach to innovation investment, potentially impacting future product development and market competitiveness.
See More
MetaVia's DA-1726 to be Presented at EASL Congress
- Clinical Research Advancement: MetaVia announced that a late-breaking abstract for its drug DA-1726 will be presented at the 2026 EASL Congress, highlighting the drug's potential in obesity treatment, which is expected to attract investor interest and enhance the company's profile.
- Best-in-Class Potential: DA-1726, as a dual agonist, has shown superior weight loss and glucose control effects in clinical trials, with the 32 mg dose demonstrating excellent results in the multiple ascending dose trial, potentially providing a competitive edge in the market.
- Mechanism Advantage: Compared to existing GLP-1 receptor agonists, DA-1726 exhibited better weight loss outcomes in mouse models while allowing for increased food intake, showcasing its unique pharmacological mechanism and clinical application prospects.
- Future Outlook: MetaVia plans to release clinical data for DA-1726 in Q4 2026, and if results are positive, it will further strengthen its positioning in the obesity treatment market and enhance the company's leadership in the biotechnology sector.
See More
MetaVia's DA-1726 to be Presented at EASL Congress
- Clinical Research Advancement: MetaVia's DA-1726, a novel dual agonist, has been accepted for poster presentation at the 2026 EASL Congress, highlighting its potential in obesity treatment and likely attracting investor and industry attention.
- Dose Optimization Study: Currently undergoing a 16-week Phase 1 Part 3 titration study, DA-1726 aims to optimize tolerability at higher doses, with data expected in Q4 2026, which will provide critical insights into its market potential.
- Superior Clinical Performance: In preclinical mouse models, DA-1726 demonstrated better weight loss compared to the existing GLP-1 agonist semaglutide, while still allowing increased food intake, showcasing its unique pharmacological advantages.
- Strategic Development Focus: With a commitment to transforming cardiometabolic diseases, the successful development of DA-1726 will further solidify MetaVia's leadership in the biotechnology sector and potentially drive future commercialization efforts.
See More
MetaVia Initiates Phase 1 Trial for DA-1726 in Obesity
- Trial Commencement: MetaVia has successfully dosed the first patient in its Phase 1 clinical trial for DA-1726, marking a significant step towards evaluating higher doses safely, which could bring new hope for obesity treatment.
- Dose Optimization Strategy: The trial is divided into two cohorts utilizing one-step and two-step dose escalation strategies aimed at safely achieving therapeutic doses of 48mg and 64mg, potentially enhancing patient tolerability and efficacy significantly.
- Promising Initial Results: At the 48mg dose, patients experienced an average weight loss of approximately 9%, alongside meaningful reductions in waist circumference and improved glycemic control, highlighting DA-1726's potential in treating obesity and related metabolic disorders.
- Future Data Expectations: More data is anticipated in the fourth quarter of 2026, with MetaVia aiming to further demonstrate DA-1726's unique efficacy and competitive advantage in the market.
See More
MetaVia Initiates Phase 1 Trial for DA-1726
- Clinical Trial Progress: MetaVia announced that the first patient has been dosed in its Phase 1 clinical trial for DA-1726, marking a significant step towards evaluating higher doses safely, which could provide new solutions for obesity treatment.
- Dose Optimization Strategy: The trial consists of two 16-week cohorts designed to assess one-step and two-step dose escalation strategies aimed at safely achieving higher therapeutic doses, thereby enhancing patient tolerability and efficacy.
- Significant Preliminary Results: At the 48 mg dose, patients experienced an average weight loss of approximately 9%, alongside meaningful reductions in waist circumference and improved glycemic control, indicating DA-1726's potential superiority over existing therapies.
- Future Outlook: More data is expected in the fourth quarter of 2026, as MetaVia focuses on further demonstrating DA-1726's efficacy, aiming for breakthrough advancements in obesity and related metabolic diseases.
See More
